Michael Vi/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) announced Monday a setback for a Phase 3 trial designed to test its Roche (OTCQX:RHHBF)-partnered leukemia therapy venetoclax as part of a combination regimen against blood cancer myelodysplastic syndrome (MDS).
Citing data from its global Phase 3 VERONA